|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.92 SEK | +2.16% |
|
+22.54% | -16.28% |
| 06-23 | Citadel Back as Public Short Seller in Synact Pharma | FW |
| 06-18 | Edison Maintains Its Valuation for Synact Pharma After Trial Results | FW |
Company Valuation: SynAct Pharma AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 3,703 | 2,416 | 314.1 | 416.8 | 1,205 | 1,007 | - | - |
| Change | - | -34.75% | -87% | 32.69% | 189.2% | -16.47% | - | - |
| Enterprise Value (EV) 1 | 3,703 | 2,416 | 314.1 | 370 | 1,152 | 989.3 | 1,032 | 1,007 |
| Change | - | -34.75% | -87% | 17.8% | 211.31% | -14.11% | 4.28% | -2.41% |
| P/E | -53.1x | -22.6x | -1.33x | -4.31x | -10.4x | -12.7x | -24.9x | - |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.7x | -0x | 0.1x | -2.4x | 0.4x | 0.5x | - |
| Capitalization / Revenue | - | - | - | - | - | 7.26x | 47.6x | 13.2x |
| EV / Revenue | - | - | - | - | - | 7.13x | 48.8x | 13.2x |
| EV / EBITDA | - | - | -1.4x | -4.11x | -9.88x | 20.5x | -34.6x | 37.4x |
| EV / EBIT | - | - | -1.4x | -4.11x | -9.88x | 20.6x | -34.4x | 37.4x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.68 | -3.6 | -6.64 | -2.08 | -2.17 | -1.49 | -0.76 | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | 138.8 | 21.15 | 76.3 |
| EBITDA 1 | - | - | -224.5 | -89.98 | -116.5 | 48.28 | -29.82 | 26.9 |
| EBIT 1 | - | - | -224.5 | -89.98 | -116.5 | 48.02 | -29.96 | 26.9 |
| Net income 1 | -69.3 | -99.2 | -215.8 | -82.4 | -110.8 | 52.18 | -26.04 | 26.9 |
| Net Debt 1 | - | - | - | -46.75 | -53.41 | -17.48 | 24.86 | - |
| Reference price 2 | 142.40 | 81.50 | 8.83 | 8.96 | 22.60 | 18.92 | 18.92 | 18.92 |
| Nbr of stocks (in thousands) | 26,006 | 29,648 | 35,571 | 46,487 | 53,330 | 53,214 | - | - |
| Announcement Date | 2/11/22 | 2/17/23 | 2/23/24 | 2/18/25 | 2/18/26 | - | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -12.7x | 7.13x | 20.49x | - | 104M | |
| 35.49x | 12.89x | 26.26x | 0.56% | 1,082B | |
| 28.11x | 6.46x | 17.57x | 2.03% | 633B | |
| 32.2x | 7.69x | 15.73x | 2.65% | 461B | |
| 18.15x | 4.51x | 11.08x | 2.94% | 338B | |
| 24.06x | 5.03x | 14.1x | 1.73% | 299B | |
| 22.19x | 5.69x | 13.74x | 2.76% | 291B | |
| 14.43x | 5.37x | 11.03x | 3.47% | 222B | |
| 24.39x | 6.45x | 11.36x | 2.7% | 202B | |
| -46.87x | 5.66x | 31.47x | 2.47% | 163B | |
| Average | 13.94x | 6.69x | 17.28x | 2.37% | 369.25B | |
| Weighted average by Cap. | 24.74x | 8.04x | 18.59x | 1.94% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SYNACT Stock
- Valuation SynAct Pharma AB
Select your edition
All financial news and data tailored to specific country editions
